tiprankstipranks
3 Best Stocks to Buy Now, 6/25/2024, According to Top Analysts
PremiumMarket News3 Best Stocks to Buy Now, 6/25/2024, According to Top Analysts
26d ago
BridgeBio gets FDA rare pediatric disease designation for BBP-418 for MD
PremiumThe Fly
BridgeBio gets FDA rare pediatric disease designation for BBP-418 for MD
1M ago
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
PremiumPress Releases
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
1M ago
Long-term achondroplasia data a ‘clear win’ for BridgeBio, says Wells Fargo
PremiumThe FlyLong-term achondroplasia data a ‘clear win’ for BridgeBio, says Wells Fargo
2M ago
BridgeBio data incrementally negative for BioMarin, says Bernstein
PremiumThe Fly
BridgeBio data incrementally negative for BioMarin, says Bernstein
2M ago
BridgeBio data remove overhang for BioMarin, says Wells Fargo
PremiumThe Fly
BridgeBio data remove overhang for BioMarin, says Wells Fargo
2M ago
BridgeBio: Acoramidis data show boost in serum TTR levels in CV outcomes at ISA
PremiumThe FlyBridgeBio: Acoramidis data show boost in serum TTR levels in CV outcomes at ISA
2M ago
BridgeBio price target lowered to $47 from $51 at UBS
PremiumThe Fly
BridgeBio price target lowered to $47 from $51 at UBS
2M ago
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
PremiumPress Releases
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100